Legend Biotech Corporation (LEGN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Legend Biotech Corporatio... (LEGN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

31.65

-0.85 (-2.62%)

At close: Jan 14, 2025, 3:59 PM

31.50

-0.47%

After-hours Jan 14, 2025, 07:48 PM EST

undefined% (undefined)

Bid	30.9
Market Cap	5.81B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.92
PE Ratio (ttm)	-16.48
Forward PE	n/a
Analyst	Buy

Ask	32.2
Volume	932,665
Avg. Volume (20D)	1,588,719
Open	32.42
Previous Close	32.50
Day's Range	30.91 - 32.51
52-Week Range	30.17 - 70.13
Beta	undefined

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 5, 2020

Employees 2,400

Stock Exchange NASDAQ

Ticker Symbol LEGN

Website https://www.legendbiotech.com

Analyst Forecast

According to 13 analyst ratings, the average rating for LEGN stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 166.98% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Legend Biotech Corporation is scheduled to release its earnings on Mar 10, 2025, before market opens.
Analysts project revenue of $172.40M, reflecting a 116.95% YoY growth and earnings per share of -0.37, making a -7.50% decrease YoY.

Why Price Moved

5 months ago · Source

+0.63%

Legend BioTech shares are trading higher. Scotiaba... Unlock content with Pro Subscription

10 months ago · Source

-4.44%

Legend Biotech shares are trading lower after the company recently announced a mixed shelf offering.

News

1 week ago · seekingalpha.com

Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple...

1 month ago · seekingalpha.com

Legend Biotech: The Story Brightens

Legend Biotech's Carvykti, a CAR-T therapy, has shown significant sales growth since being launched in 2022. The company has some $1.2 billion in cash on its balance sheet and losses are projected to ...

2 months ago · seekingalpha.com

Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript

Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang ...

2 months ago · zacks.com

Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with W...

2 months ago · zacks.com

Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate ...

2 months ago · zacks.com

Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade

The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...